Sillberg Victoria A H, Perry Jeffrey J, Stiell Ian G, Wells George A
Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Resuscitation. 2008 Dec;79(3):380-6. doi: 10.1016/j.resuscitation.2008.07.020. Epub 2008 Oct 31.
No evidence supports vasopressin over epinephrine in cardiac arrest; however animal and some clinical studies support their concurrent use. This systematic review compares the efficacy of vasopressin and epinephrine used together versus repeated doses of epinephrine alone in cardiac arrest.
We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials. We included randomized controlled trials (RCTs) where vasopressin and epinephrine were administered concurrently to cardiac arrest patients within the half-life of vasopressin. Two reviewers assessed studies for eligibility, data extraction and quality. Appropriateness of studies for meta-analysis was assessed. The primary outcome was survival to hospital discharge and the secondary outcome was return of spontaneous circulation (ROSC).
From 235 titles identified, we reviewed 29 abstracts. Three cardiac arrest studies were included (N=1226). Study 1 randomized vasopressin versus epinephrine then subsequent epinephrine. Study 2 randomized two doses of vasopressin versus epinephrine. Study 3 randomized vasopressin versus placebo, administered following initial epinephrine. All studies favored combination treatment for ROSC, but only study 2 was statistically significant (RR 1.42, 95% CI 1.14-1.77). Studies 1 and 2 reported survival to discharge, only study 2 was significant (RR 3.69, 95% CI 1.52-8.95). The methods for the three studies were too dissimilar to allow pooling of results.
This systematic review of the combination of vasopressin and epinephrine found trends towards better ROSC but equivocal effects on survival. At the present time, there is inadequate evidence to advocate the sequential use of vasopressin and epinephrine for cardiac arrest.
在心脏骤停时,尚无证据支持血管加压素优于肾上腺素;然而,动物研究和一些临床研究支持两者联合使用。本系统评价比较了心脏骤停时血管加压素与肾上腺素联合使用和单独重复使用肾上腺素的疗效。
我们检索了MEDLINE、EMBASE和Cochrane对照试验中心注册库。我们纳入了在血管加压素半衰期内将血管加压素和肾上腺素同时给予心脏骤停患者的随机对照试验(RCT)。两名评价者评估研究的合格性、数据提取和质量。评估纳入荟萃分析的研究的适宜性。主要结局是存活至出院,次要结局是自主循环恢复(ROSC)。
从识别出的235篇标题中,我们回顾了29篇摘要。纳入了三项心脏骤停研究(N = 1226)。研究1将血管加压素与肾上腺素随机分组,然后给予后续肾上腺素。研究2将两剂血管加压素与肾上腺素随机分组。研究3将血管加压素与安慰剂随机分组,在初始肾上腺素给药后给予。所有研究均支持联合治疗以实现ROSC,但只有研究2具有统计学意义(RR 1.42,95%CI 1.14 - 1.77)。研究1和2报告了出院存活率,只有研究2具有显著性(RR 3.69,95%CI 1.52 - 8.95)。三项研究的方法差异太大,无法合并结果。
本对血管加压素和肾上腺素联合使用的系统评价发现,联合使用在实现更好的ROSC方面有趋势,但对存活率的影响不明确。目前,没有足够的证据支持在心脏骤停时序贯使用血管加压素和肾上腺素。